DFTX at a glance
Definium Therapeutics, Inc. (DFTX, SEC CIK 1813814) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on August 6, 2026, an 8-K current report on September 14, 2026 and Form 4 insider filings as recently as September 29, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- As of June 30, 2026, 33 institutional investment managers tracked by SignalX reported holding Definium Therapeutics, Inc. (DFTX) shares worth $1.8 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Sullivan Mark on September 25, 2026 of 14,051 shares at $36.57 per share.
- In the last 90 days, DFTX insiders reported 0 open-market purchases ($0) and 6 open-market sales ($3.0M) on Form 4, a net sale of $3.0M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Insiders · 90 days
- 0 buys · 6 sells
- Net −$3.0M
- 13F holders
- 33 funds
- $1.8B · +6 vs prior quarter
- Latest 8-K
- Sep 14, 2026
- Item 8.01 · Item 7.01
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business: late-stage clinical biopharma developing psychedelics-based treatments for brain health disorders
- New emphasis on Phase 3 trials for DT120 ODT targeting GAD and MDD; initiated DT402 Phase 2a trial for autism spectrum disorder in late 2025
- Strategic shift: rebranded from MindMed to Definium Therapeutics in January 2026, began trading as “DFTX” on Nasdaq
- Quantitative highlight: DT120 Phase 2b GAD trial showed 7.6-point HAM-A improvement vs placebo (p<0.0004) with 65% response rate sustained to 12 weeks
- Noteworthy: FDA granted Breakthrough Therapy designation for DT120 in GAD and UK’s MHRA issued Innovation Passport designation in 2024
Risk Factors
- Regulatory risk: FDA breakthrough designation for DT120 in GAD requires successful Phase 3 trials (Voyage, Panorama) with topline readouts in 2026
- Geopolitical/macro risk: Clinical trial enrollment and drug supply dependent on U.S. regulations and foreign currency exchange fluctuations affecting expenses
- Operational risk: Dependence on contract research and manufacturing organizations for clinical trials and cGMP-compliant product supply
- Competitive risk: Psychedelic drug market includes competitors developing alternative therapies for brain health disorders (no named competitor disclosed)
- Financial risk: $411.6M cash as of Dec 31, 2025, expected funding into 2028, but reliance on future equity/debt raises could dilute shareholders or impose restrictive covenants
Management Discussion & Analysis
- Forward-looking statements mentioned with general risk disclosure but no specific guidance or outlook
AI summary of the DFTX 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Revenue $0, unchanged YoY; no product candidates commercialized
- Net loss $159.0M vs $42.7M YoY; operating loss $75.1M vs $40.9M
- Highest R&D spending DT120 GAD $22.6M; DT402 lowest at $0.4M
- Cash, equivalents and investments approximately $1.1B; June offering net proceeds $757.9M
- Cash runway into 2030; Voyage and Panorama readouts anticipated August and September 2026
AI summary of the DFTX 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 8.01: Other Events
- September 14, 2026 press release and Panorama topline data presentation filed as substantive exhibits
- Panorama study results likely represent a material clinical-development update for Definium Therapeutics
Item 7.01: Regulation FD Disclosure
- Exhibit 99.1 furnished under Regulation FD, not treated as filed under Exchange Act Section 18
- Exhibit excluded from automatic incorporation into Definium Therapeutics SEC filings
Item EX-99.1: Item EX-99.1
- Panorama met primary and all key secondary endpoints in 245-patient Phase 3 GAD trial, reinforcing DT120 ODT’s regulatory case
- HAM-A placebo-adjusted improvement reached 5.1 points at Week 12, with p<0.0001 and Cohen’s d=0.64
Item 8.01: Other Events
- FDA breakthrough designation granted to DT120 ODT for major depressive disorder
- Potentially faster FDA development and review pathway for DT120 ODT
Item EX-99.1: Item EX-99.1
- FDA Breakthrough Therapy designation for DT120 in MDD, accelerating potential development and review
- Phase 3 Emerge: 8.1-point placebo-adjusted MADRS improvement at Week 6, p<0.0001
Item 7.01: Regulation FD Disclosure
- Positive topline Phase 3 Voyage data for DT120 ODT in generalized anxiety disorder
- Potential regulatory and commercialization catalyst for Definium’s lead program
Item 8.01: Other Events
- August 12, 2026 press release and Voyage topline data presentation filed as exhibits
- Voyage data may materially influence DFTX’s clinical-development outlook and investor expectations
Item EX-99.1: Item EX-99.1
- Phase 3 Voyage met primary and all key secondary endpoints in 214 GAD patients, materially advancing DT120 ODT toward potential approval
- HAM-A improvement at Week 12: -11.6 DT120 versus -6.2 placebo, placebo-adjusted difference 5.4 points, p<0.0001, Cohen’s d=0.81
AI summaries of DFTX 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for DFTX
Don't miss the next DFTX filing
- Alerts as it files. A push when DFTX files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut DFTX, by share count.
- Ask anything. An AI agent that reads every DFTX filing and answers with sources.
DFTX alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Sullivan Mark | Sell | Sep 25, 2026 | 14,051 | $36.57 |
| Karlin Daniel | Sell | Sep 25, 2026 | 10,853 | $36.57 |
| Barrow Robert | Sell | Sep 25, 2026 | 31,550 | $36.57 |
| Wiley Matthew T. | Sell | Sep 25, 2026 | 3,097 | $36.57 |
| Roberts Brandi | Sell | Sep 25, 2026 | 3,377 | $36.57 |
| Vallone Carol A | M | Sep 18, 2026 | 1,086 | $35.52 |
| Vallone Carol A | M | Sep 18, 2026 | 1,086 | - |
| Krebs Andreas | M | Sep 18, 2026 | 1,629 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|
| Profitability | ||||
| Operating Income | -$93.9M | -$103.9M | -$166.3M | |
| Net Income | -$95.7M | -$108.7M | -$183.8M | |
| Balance Sheet | ||||
| Total Assets | $124.5M | $302.2M | $440.1M | |
| Equity | $78.1M | $241.4M | $332.3M | |
| ROE | -122.5% | -45.0% | -55.3% | |
| Per Share | ||||
| EPS | $-2.44 | $-1.54 | $-2.06 | |
| Cash Flow | ||||
| Operating CF | -$64.4M | -$79.1M | -$131.6M | |
Source: XBRL data in Definium Therapeutics, Inc. (DFTX)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate DFTX share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 33 | $1.76B |
| Q1 2026 | 27 | $459.5M |
| Q4 2025 | 1 | $700,000 |
- T. Rowe Price Group+4.58M (+6546%)
- FMR LLC (Fidelity)+2.94M (+163%)
- BlackRock+2.75M (+32%)
- Vanguard Portfolio Management LLC+775.8K (+89%)
- State Street Corp+593.5K (+24%)
- Millennium Management−580.8K (-69%)
- Two Sigma Investments−279.8K (-23%)
- Marex Group plc−13.2K (-66%)
- Raymond James Financial−1.3K (-6%)
- Franklin Resources+486.2K
- Prudential Financial+15.5K
- Principal Financial Group+10.0K
- Mangrove Partners+9.1K
- U.S. Bancorp+1.3K
Source: 13F-HR filings on SEC EDGAR (aggregated from 61 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
DFTX filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Sep 29, 2026 | - | - | - |
| 4 | Sep 29, 2026 | - | - | - |
| 4 | Sep 29, 2026 | - | - | - |
| 4 | Sep 29, 2026 | - | - | - |
| 4 | Sep 29, 2026 | - | - | - |
| 4 | Sep 18, 2026 | - | - | - |
| 4 | Sep 18, 2026 | - | - | - |
| 4 | Sep 14, 2026 | - | - | - |
| 4 | Sep 14, 2026 | - | - | - |
| 8-K | Sep 14, 2026 | - | Analysis | - |
| 4 | Sep 14, 2026 | - | - | - |
| 4 | Sep 14, 2026 | - | - | - |
| 4 | Sep 14, 2026 | - | - | - |
| 8-K | Sep 8, 2026 | - | Analysis | - |
| 4 | Sep 4, 2026 | - | - | - |
| 8-K | Aug 12, 2026 | - | Analysis | - |
| 4 | Aug 12, 2026 | - | - | - |
| 4 | Aug 12, 2026 | - | - | - |
| 4 | Aug 12, 2026 | - | - | - |
| 4 | Aug 12, 2026 | - | - | - |
| 4 | Aug 12, 2026 | - | - | - |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 10-Q | Aug 6, 2026 | Jun 30, 2026 | Analysis | |
| 4 | Jun 26, 2026 | - | - | - |
| 4 | Jun 26, 2026 | - | - | - |
Related Health Care companies
- BTMD · biote Corp.Medicinal Chemicals & Botanical Products
- FTLF · FITLIFE BRANDS, INC.Medicinal Chemicals & Botanical Products
- MDWD · MediWound Ltd.Medicinal Chemicals & Botanical Products
- NAGE · Niagen Bioscience, Inc.Medicinal Chemicals & Botanical Products
- USNA · USANA HEALTH SCIENCES INCMedicinal Chemicals & Botanical Products
- TXG · 10x Genomics, Inc.Laboratory Analytical Instruments
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
DFTX SEC filings: frequently asked questions
Are DFTX insiders buying or selling?
In the last 90 days, Definium Therapeutics, Inc. (DFTX) officers, directors and 10% owners reported no open-market purchases and 6 open-market sales worth $3.0 million by 5 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold DFTX stock?
As of June 30, 2026, the largest Definium Therapeutics, Inc. (DFTX) holders among the 13F filers tracked by SignalX were BlackRock ($528.4 million), FMR LLC (Fidelity) ($223.6 million), T. Rowe Price Group ($218.8 million), State Street Corp ($144.2 million), Goldman Sachs Group ($84.7 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What are the main risks in DFTX's latest 10-K?
In the 10-K filed February 26, 2026, Definium Therapeutics, Inc. (DFTX) flagged: Regulatory risk: FDA breakthrough designation for DT120 in GAD requires successful Phase 3 trials (Voyage, Panorama) with topline readouts in 2026. Geopolitical/macro risk: Clinical trial enrollment and drug supply dependent on U.S. regulations and foreign currency exchange fluctuations affecting expenses. (AI summary of the Risk Factors section.)
What did DFTX report in its latest 8-K?
Definium Therapeutics, Inc. (DFTX) filed an 8-K on September 14, 2026 reporting Item 8.01 (Other Events) and Item 7.01 (Regulation FD Disclosure). September 14, 2026 press release and Panorama topline data presentation filed as substantive exhibits.
What are the latest DFTX SEC filings?
Definium Therapeutics, Inc. (DFTX) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on August 6, 2026, an 8-K current report on September 14, 2026 and a Form 4 insider filing on September 29, 2026.
What is DFTX's SEC CIK number?
Definium Therapeutics, Inc. (DFTX)'s SEC Central Index Key (CIK) is 1813814. EDGAR lists every DFTX filing under that number.
Ask anything about DFTX
The research agent reads DFTX's filings, financials, insider trades and 13F holders, then answers with sources.